[Daily Medi Reporter Jeongyeon Park]
嘉泉大学吉医院 and the 嘉泉大学产学合作团 recently signed a 技术转让 agreement with RudaCure for a '制药 composition for treating 角膜损伤.'
The technology held by 嘉泉大学吉医院 and the 嘉泉大学产学合作团 is a 专利ed technology for a '制药 composition for treating 角膜损伤 containing 8-oxo-2'-deoxyguanosine or a 制药ly acceptable salt thereof as an active ingredient,' jointly developed by Professor Donghyun Kim of the Department of Ophthalmology and Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine.
Unlike existing drugs that merely alleviate 干眼症, this technology is characterized by fundamentally suppressing the mechanism that causes 干眼症, giving it high potential for developing treatments for 干眼症 and related 眼部 conditions.
Director Myunghee Chung of the Gachon Institute of Life Sciences and Medicine stated, "This research is meaningful in that it represents a 专利ed technology for fundamentally treating the growing number of age-related 眼部 diseases," adding, "We will cooperate with RudaCure to ensure that this technology moves beyond research and translates into outcomes that are truly necessary for patients."
RudaCure, a company developing both protein therapeutics and synthetic drugs for pain and age-related 眼部 diseases,